Join Verpora at EPP Life Sciences Pricing Forum 2023 - the must-attend conference for pricing directors and executives, and all of those involved in pricing, market access and reimbursement for the Pharmaceutical, MedTech and Biotech industries.
Day Two’s program includes Verpora Head of Payers, Omar Ali, presenting a payers perspective of value based contracting with innovative medicines in his talk “Can we afford a cure?”.
Omar is also ready to field your questions during Day One’s panel discussion, with a focus on “Supporting Sustainable Access Through Equitable Pricing Principles”, alongside Benoît Donze - Director, EU Pricing & Reimbursement Lead - Amarin Corporation, and Enric Muñoz - Sr. Director, Global Market Access - Global Rx Pricing Head - Galderma.
The annual EPP Life Sciences Pricing Forum offers you a unique opportunity to discover best practices and leading-edge solutions, interact with your peers from different countries, engage in insightful discussions, share experiences and gain new perspectives. Join us for this one-of-a-kind lively and interactive conference, with tremendous networking opportunities and dedicated learning sessions to help you learn, grow and best prepare for the pricing challenges ahead.
The event offers the opportunity to talk about many urgent issues that the industry is facing in these days. With so many new regulations, inflation and rising production costs, new products and new pricing models… how are we going to move forward successfully in this new world? Innovative treatments and revolutionary drugs and tools are ready to be launched in the market, but costs and regulations are hampering efforts to build strong and sustainable pricing, access and reimbursement models. Customers are getting more demanding – quality and equity are paramount issues that we must face aggressively.
More Info & Registration
More information and registration directly via the Pharma Pricing Innovation Conference website…
Representing Verpora
Omar Ali
Head of Payers, Verpora
Formulary Development Pharmacist, Surrey & Sussex NHS Trust
NHS Managed Entry of New Drugs
NHS Drugs & Therapeutics Committee Appraisals
NICE Health Economics, Health Efficiency & Health Technology Assessment
Specialties
NHS Payer Advisory Boards for Pharma
NHS White Paper & GP Commissioning
EU5/US Payer Advisory Boards on Pricing & Reimbursement Pharmaceuticals
Value Based Pricing & Impact on Pharma
